ストックスクリーナーアプリを入手
32.80
1.83%
-0.61
前日終値:
$33.41
開ける：
$33.56
24時間の取引高:
182.17K
Relative Volume:
0.59
時価総額：
$2.29B
収益：
-
当期純損益:
$-195.21M
株価収益率:
-10.33
EPS:
-3.1763
ネットキャッシュフロー:
$-176.19M
1週間 パフォーマンス:
+1.86%
1か月 パフォーマンス:
+13.85%
6か月 パフォーマンス:
+36.55%
1年 パフォーマンス:
+97.12%
1日の値動き範囲:
$32.34
$34.41
1週間の範囲:
$30.49
$34.41
52週間の値動き範囲:
$16.72
$34.41
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
32.80 | 2.29B | 0 | -195.21M | -176.19M | -3.1763 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-09 | 開始されました | Wolfe Research | Outperform |
| 2026-03-09 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-10-15 | 開始されました | H.C. Wainwright | Buy |
| 2025-10-09 | アップグレード | BofA Securities | Underperform → Neutral |
| 2025-06-11 | 開始されました | Guggenheim | Buy |
| 2025-04-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-09-25 | 開始されました | Wedbush | Outperform |
| 2023-08-15 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-05 | 開始されました | Bryan Garnier | Buy |
| 2022-09-13 | 再開されました | JMP Securities | Mkt Outperform |
| 2022-08-23 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-22 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-05-25 | 開始されました | JMP Securities | Mkt Outperform |
| 2021-03-02 | 開始されました | BofA Securities | Neutral |
| 2021-03-02 | 開始されました | Morgan Stanley | Overweight |
| 2021-03-02 | 開始されました | Oppenheimer | Outperform |
| 2021-03-02 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Pharvaris Nv (PHVS) 最新ニュース
PHVS reports 10b5-1 sales and option exercise (PHVS) - Stock Titan
Pharvaris NV (PHVS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pharvaris (PHVS) CEO Modig sells 2,291 shares in planned Rule 10b5-1 trades - Stock Titan
Pharvaris NV (PHVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Pharvaris NV (PHVS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Pharvaris NV (PHVS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Pharvaris NV (PHVS) Institutional Confidence - TradingKey
Pharvaris NV (PHVS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Pharvaris NV (PHVS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Why (PHVS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Pharvaris (PHVS) CMO Lu Peng has 117 RSU shares withheld for taxes - Stock Titan
Pharvaris stock rating reiterated at Buy by H.C. Wainwright on safety data - Investing.com
PHVS Technical Analysis & Stock Price Forecast - Intellectia AI
Pharvaris (PHVS) CMO reports 109 shares withheld for RSU tax obligations - Stock Titan
PHVS (NASDAQ: PHVS) Rule 144 notice lists 2,291 RSUs; recent 10b5-1 sales noted - Stock Titan
Single capsule rapidly eased most HAE attacks in Pharvaris study - Stock Titan
Pharvaris NV (PHVS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Pharvaris N.V. (PHVS) Presents at World Orphan Drug Congress (WODC) USA 2026Slideshow - Seeking Alpha
Pharvaris (PHVS) Shows Modest Gains After Recent Pullback, Testing Key ResistanceSystematic Flow - newsline.com
Saturn V Capital Management LP's Pharvaris NV(PHVS) Holding History - GuruFocus
Does Pharvaris (PHVS) have the potential to rally 59.93% as Wall Street analysts expect? - MSN
Pharvaris Sets June 26, 2026 AGM as Late-Stage Angioedema Programs Advance - TipRanks
Pharvaris (Nasdaq: PHVS) details AGM plans and NDA timeline for HAE therapy - Stock Titan
Shareholders of Pharvaris to vote at June 26 annual meeting - Stock Titan
Why Pharvaris (PHVS) Is Up 8.6% After Expanding Deucrictibant HAE Data And Regulatory Plans - Sahm
Pharvaris N.V. (PHVS) Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Progress in HAE Pipeline - newsline.com
Pharvaris Chief Medical Officer Sells 14,000 Shares for $427,000 - AOL.com
Insider Sell: Anna Nijdam Sells Shares of Pharvaris NV (PHVS) - GuruFocus
Pharvaris (PHVS) accounting officer sells 2,670 common shares on market - Stock Titan
A Look At Pharvaris (PHVS) Valuation As Deucrictibant Data Advances Toward Key EAACI 2026 Catalyst - Sahm
Understanding Momentum Shifts in (PHVS) - Stock Traders Daily
Anna Nijdam reports sales of PHVS common shares (PHVS) - Stock Titan
PHVS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Pharvaris N.V. (PHVS) Presents at The 2026 Eastern Allergy ConferenceSlideshow (NASDAQ:PHVS) 2026-05-30 - Seeking Alpha
Pharvaris (PHVS) Holds Near Resistance as Shares Edge Higher on Modest VolumeRetail Driven Moves - The Legal Advocate
Pharvaris Trades Flat as Investors Wait for June Data Update - Bez Kabli
Pharvaris (PHVS) Edges Higher Amid Tight Trading Range, Testing Resistance at $31.61Death Cross - The Legal Advocate
Hereditary angioedema oral drug data headed to European allergy congress - Stock Titan
Pharvaris (PHVS) director Monges sells 9,667 shares, updates ownership - Stock Titan
Pharvaris (PHVS) accounting officer exercises options, sells 7,330 shares - Stock Titan
Pharvaris (PHVS) CFO/CLO Nassif sells 10,000 shares, corrects ownership - Stock Titan
Oppenheimer maintains Pharvaris NV (PHVS) outperform recommendation - MSN
Avoiding Lag: Real-Time Signals in (PHVS) Movement - Stock Traders Daily
B of A Securities Upgrades Pharvaris N.V. (PHVS) - MSN
Anna Nijdam proposes sale of 5,501 PHVS shares via Morgan Stanley (PHVS) - Stock Titan
Pharvaris (PHVS) director sells 10,000 shares, exercises options under 10b5-1 - Stock Titan
Pharvaris (PHVS) CEO Berndt Modig updates direct and indirect share holdings - Stock Titan
[144] Pharvaris N.V. SEC Filing - Stock Titan
Pharvaris (PHVS) CEO Modig sells 2,292 shares under Rule 10b5-1 plan - Stock Titan
PHVS (NASDAQ) Form 144/A: brokered resale of 4,667 and 5,333 common shares - Stock Titan
Director Robert Glassman of Pharvaris (PHVS) sells 10,000 shares after exercising options - Stock Titan
Pharvaris Nv (PHVS) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):